A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
NCT ID: NCT01214720
Last Updated: 2014-08-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
607 participants
INTERVENTIONAL
2005-07-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer
NCT00260364
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
NCT00100815
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
NCT00365144
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
NCT00841035
Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
NCT01077986
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
bevacizumab [Avastin]
Intervenous repeating dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bevacizumab [Avastin]
Intervenous repeating dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* metastatic pancreatic cancer (adenocarcinoma);
* good liver, kidney, and bone marrow function.
Exclusion Criteria
* pregnant or lactating females;
* fertile men, or women of childbearing potential, not using adequate contraception;
* major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start;
* current or recent treatment (within 30 days prior to starting study treatment) with another investigational drug, or participation in another investigational study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Adelaide, , Australia
Camperdown, , Australia
Footscray, , Australia
Heidelberg, , Australia
Kurralta Park, , Australia
Melbourne, , Australia
Melbourne, , Australia
St Leonards, , Australia
Sydney, , Australia
Sydney, , Australia
Graz, , Austria
Innsbruck, , Austria
Salzburg, , Austria
Vienna, , Austria
Antwerp, , Belgium
Brussels, , Belgium
Brussels, , Belgium
Leuven, , Belgium
Wilrijk, , Belgium
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Québec, Quebec, Canada
Beijing, , China
Beijing, , China
Shanghai, , China
Brno, , Czechia
Hradec Králové, , Czechia
Helsinki, , Finland
Besançon, , France
Bordeaux, , France
Boulogne-Billancourt, , France
Clichy, , France
Limoges, , France
Marseille, , France
Paris, , France
Paris, , France
Rouen, , France
Saint-Herblain, , France
Strasbourg, , France
Berlin, , Germany
Bochum, , Germany
Bonn, , Germany
Halle, , Germany
Hamburg, , Germany
Heidelberg, , Germany
Leipzig, , Germany
Magdeburg, , Germany
Mainz, , Germany
Mönchengladbach, , Germany
München, , Germany
Trier, , Germany
Kfar Saba, , Israel
Petah Tikva, , Israel
Rehovot, , Israel
Tel Aviv, , Israel
Bergamo, , Italy
Bologna, , Italy
Brescia, , Italy
Chieti, , Italy
Genova, , Italy
Napoli, , Italy
Orbassano, , Italy
Parma, , Italy
San Giovanni Rotondo, , Italy
Amsterdam, , Netherlands
Auckland, , New Zealand
Christchurch, , New Zealand
Lima, , Peru
Lima, , Peru
Gliwice, , Poland
Lublin, , Poland
Szczecin, , Poland
Wroclaw, , Poland
Singapore, , Singapore
Singapore, , Singapore
Cape Town, , South Africa
Pretoria, , South Africa
Alicante, , Spain
Barcelona, , Spain
Barcelona, , Spain
Barcelona, , Spain
Barcelona, , Spain
Córdoba, , Spain
Elche, , Spain
Madrid, , Spain
Santander, , Spain
Valencia, , Spain
Valencia, , Spain
Stockholm, , Sweden
Kueishan, , Taiwan
Taipei, , Taiwan
Glasgow, , United Kingdom
Leicester, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Northwood, , United Kingdom
Sutton, , United Kingdom
Truro, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BO17706
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.